YOLFTbeta
Imagion Biosystems Ltd

Imagion Biosystems Ltd

IBX · AU · Healthcare / Diagnostics & Research

0.005AUD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.005
Open0.005
Day Range0.005 – 0.005
52-Week Range0.007 – 0.04
Volume370.98K
Market Cap5.61M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta-0.23
50-Day Avg0.0097
200-Day Avg0.0169

About

Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to magnetic relaxometry. The company has collaboration agreement with Wayne State University to develop optimised MRI sequences which is in Phase 2 study of for the MagSense imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in Melbourne, Australia.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Robert Romeo Proulx
  • Employees0
  • HeadquartersSuite 2, Melbourne, VIC, Australia, 3000, Australia
  • Websitehttps://imagionbiosystems.com

Leadership

  • Mr. Robert Romeo ProulxExecutive Chairman · b. 1958
  • Ms. Melanie Leydin C.A.Non-Executive Director & Company Secretary
  • Mr. Ward DetwilerPresident of US Operations & Chief Business Officer

Financials

Income Statement

Currency: AUD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue6.11K5.49K1220.10K191.48K410.85K205.72K232.87K473.43K1.08M2.67M32.37K
Growth (%)--10.11%-99.78%+167416.67%+852.53%+114.57%-49.93%+13.20%+103.31%+128.74%+146.10%-98.79%
Cost of Revenue0021.64K03.30M2.27M2.86M2.70M3.62M5.25M401.04K8.81K
Gross Profit6.11K5.49K-21.63K20.10K-3.10M-1.86M-2.66M-2.47M-3.14M-279.83K2.26M-8.81K
Gross Margin100.00%100.00%-180250.00%100.00%-1621.19%-452.27%-1290.63%-1061.20%-663.76%-25.84%84.95%-27.21%
Operating Expense2.33M4.13M544.94K6.88M5.23M1.57M5.10M5.84M9.00M15.35M3.02M3.58M
Operating Income-2.32M-4.12M-566.57K-6.86M-8.33M-3.42M-7.76M-8.31M-12.14M-15.63M-756.55K-3.58M
Operating Margin-37959.99%-75099.99%-4721416.67%-34122.66%-4351.57%-833.23%-3771.72%-3570.53%-2564.09%-1443.74%-28.39%-11074.74%
EBITDA-2.27M-3.97M-779.61K-6.65M-8.12M-3.27M-7.16M-5.62M-11.03M-10.30M-700.09K-3.58M
EBITDA Margin-37179.98%-72274.99%-6496766.67%-33093.74%-4239.92%-796.47%-3478.15%-2411.68%-2328.90%-951.58%-26.27%-11047.53%
Net Income-2.51M-4.40M-1.03M-7.79M-8.35M-3.43M-5.36M-6.02M-9.81M-12.47M-2.07M-4.31M
Net Income Margin-41159.99%-80124.99%-8620641.67%-38775.26%-4359.67%-835.46%-2607.47%-2587.21%-2071.95%-1151.86%-77.56%-13313.12%
R&D2.24M3.88M502.07K2.16M3.30M2.27M2.86M2.70M3.62M5.25M401.04K2.10M
R&D as % of Total Revenue36639.99%70724.99%4183916.67%10723.88%1721.19%552.27%1390.63%1161.20%763.76%484.85%15.05%6495.51%
Interest Expense000935.26K7.75K9.16K43.85K7.82K174.33K1.13M1.14M847.58K
Interest Expense % of Total Revenue0.00%0.00%0.00%4652.60%4.05%2.23%21.32%3.36%36.82%104.16%42.85%2618.40%

Balance Sheet

Currency: AUD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets338.51K788.19K12.14M7.64M5.19M4.87M14.12M14.12M9.98M4.59M2.80M2.04M
Total Liabilities4.31M9.65M451.99K688.77K1.32M1.90M1.21M809.88K5.30M8.37M5.09M4.21M
Total Equity-3.97M-8.86M11.69M6.95M3.87M2.97M12.91M13.31M4.68M-3.79M-2.28M-2.16M
Cash162.53K388.60K11.91M6.87M4.37M3.40M13.20M13.39M4.45M227.08K2.67M1.85M
Total Debt4.19M9.49M13.93M80.01K54.52K876.78K660.98K46.02K4.60M6.04M2.85M2.56M
Net Debt4.03M9.11M2.01M-6.79M-4.31M-2.52M-12.54M-13.35M158.27K5.81M176.78K716.72K

Cash Flow

Currency: AUD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.43M-4.22M-267.26K-6.98M-8.13M-4.18M-4.62M-5.07M-8.07M-8.32M-1.27M-4.04M
Investing Cash Flow-43.99K-357.02K-369.61K-369.61K-83.56K-12.35K-7.86K-310.09K-468.73K-190.38K83.74K0
Financing Cash Flow2.17M4.79M231.48K14.19M4.10M3.33M14.52M5.15M-962.06K4.29M3.61M3.24M
Capital Expenditure43.99K357.02K369.61K369.61K83.56K12.35K7.86K218.83K507.31K190.38K14
Free Cash Flow-2.47M-4.58M-267.26K-7.35M-8.22M-4.19M-4.63M-5.29M-9.21M-8.51M-1.27M-4.04M
Dividends Paid---294.54K-35.40K480.62K359.25K----
FCF to OCF101.81%108.45%100.00%105.30%101.03%100.30%100.17%104.32%114.05%102.29%100.00%100.00%
Dividend Paid to FCF----4.01%--0.84%-10.38%-6.79%----

Earnings

Report DateFeb 28, 2018Aug 23, 2018Mar 29, 2019Aug 29, 2019Feb 27, 2020Aug 25, 2020Feb 25, 2021Aug 17, 2021Feb 24, 2022Aug 24, 2022Jan 30, 2023Feb 28, 2025Aug 28, 2025
EPS Estimate0.000.000.000.000.000.000.000.00--0.000.00-
EPS Actual-0.03-0.02-0.020.00-0.010.000.000.00-0.01-0.010.00-0.01-0.01
Surprise-------------
Timing---------After-hoursAfter-hours-Pre-market

Key Statistics & Ratios

Market Cap5.61M
Enterprise Value7.73M
Trailing P/E0.00
Forward P/E0.00
Price / Sales9.78
Price / Book3.84
EPS-0.01
Book Value-0.006
Revenue (TTM)573.23K
Gross Profit (TTM)-2.51M
EBITDA-4.10M
Profit Margin0.00%
Operating Margin-331.40%
Return on Equity-2804.87%
Return on Assets-319.68%
Shares Outstanding801.01M
Shares Float386.07M
Beta-0.23
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Nov 16, 20231:40
  • Mar 27, 202021:20
  • Sep 27, 20189:8